ReviewTherapeutic advances in hematology2018

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Tristan Knight et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.